Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

References

• Leonard J P, Schattner E J, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001; 13: 342–347
   PubMed Web of Science ®Google Scholar
• Argatoff L H, Connors J M, Klasa R J, Horsman D E, Gascoyne R D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078
   PubMed Web of Science ®Google Scholar
• Fisher R I, Dahlberg S, Nathwani B N, Banks P M, Miller T P, Grogan T M. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85: 1075–1082
   PubMed Web of Science ®Google Scholar
• Teodorovic I, Pittaluga S, Kluin-Nelemans J C, Meerwaldt J H, Hagenbeek A, van Glabbeke M, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819–2826
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Frederick B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, Boral A, et al. Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study. J Clin Oncol 2006; 24: 7512, Meeting abstracts
   Google Scholar
• Hollister D, Silver R T, Gordon B, Coleman M. Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer 1982; 50: 1690–1694
   PubMed Web of Science ®Google Scholar
• Coleman M, Boyd D B, Bernhardt B. COPBLAM: Infusion chemotherapy for large cell lymphoma. Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy, C J Rosenthal, M Rotman. Plenum, New York, NY 1986; 79–86
   Google Scholar
• George P, Coleman M. The C3 regimen for resistant lymphoma: daily oral etoposide, chlorambucil, procarbazine, and prednisone. ASCO Meet Abstr 1993; 12: 379
   Google Scholar
• Boyd D B, Coleman M, Papish S D. COPBLAM III: infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol 1988; 6: 425–433
   PubMed Web of Science ®Google Scholar
• Coleman M, Ruan J, Furman R R, Niesvizky R, Martin P, Leonard J P. Oral combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide): low-dose continuous metronomic multidrug therapy. ASCO Meet Abstr 2007; 25: 8064
   Google Scholar
• Shaked Y, Emmenegger U, Francia G. Low dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65: 7045–7051
   PubMed Web of Science ®Google Scholar
• Emmenegger U, Man S, Shaked Y. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimen. Cancer Res 2004; 64: 3994–4000
   PubMed Web of Science ®Google Scholar
• Man S, Bocce G, Francia G. Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered through the drinking water. Cancer Res 2002; 62: 2731–2735
   PubMed Web of Science ®Google Scholar
• Kerbel R S, Klement G, Pritchard K I, Kamen B. Continuous low dose anti-angiogenesis/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12–15
   PubMed Web of Science ®Google Scholar
• Buchstein R, Kerbel R S, Shaked Y. High dose celecoxib and metronomic “low dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 5190–5198
   PubMed Web of Science ®Google Scholar
• Emmenger U, Morton G C, Francia G. Low dose metronomic daily cyclophosphamide and weekly tirapazamine: a well tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006; 66: 1664–1674
   PubMed Web of Science ®Google Scholar
• Shaked Y, Emmengger U, Man S. Optimal biologic dose of metronomic chemotherapy regimen is associated with maximum antiangiogenic activity. Blood 2005; 106: 3058–3061
   PubMed Web of Science ®Google Scholar